Similarly, in a mouse model of CLL, Hanna et al. demonstrated that ibrutinib plus antibodies that disrupt the PD-1/PD-L1 axis enhanced CD8+ T cell effector activity [46]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.